Gilead's storied hep C franchise will now include a generic drug operation
Faced with a dwindling stream of revenue for its hepatitis C franchise amid an ongoing national debate on drug pricing, Gilead has come up with an unconventional plan.
Through a new subsidiary named Asegua Therapeutics, Gilead will sell generic versions of the hepatitis C combo drugs Epclusa and Harvoni at a price of $24,000 — a fraction of the list prices of the drugs, which cost $75,000 and $94,500 respectively for a 12-week regimen.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.